Oncology Impact Fund (cayman) Management L.p. - Net Worth and Insider Trading
Oncology Impact Fund (cayman) Management L.p. Net Worth
The estimated net worth of Oncology Impact Fund (cayman) Management L.p. is at least $157 Million dollars as of 2024-11-13. Oncology Impact Fund (cayman) Management L.p. is the 10% Owner of Cullinan Therapeutics Inc and owns about 7,648,268 shares of Cullinan Therapeutics Inc (CGEM) stock worth over $123 Million. Oncology Impact Fund (cayman) Management L.p. is the 10% Owner of Harpoon Therapeutics Inc and owns about 1,278,514 shares of Harpoon Therapeutics Inc (HARP) stock worth over $29 Million. Oncology Impact Fund (cayman) Management L.p. is also the 10% Owner of TCR2 Therapeutics Inc and owns about 3,370,982 shares of TCR2 Therapeutics Inc (TCRR) stock worth over $5 Million. Besides these, Oncology Impact Fund (cayman) Management L.p. also holds Oncorus Inc (ONCR) . Details can be seen in Oncology Impact Fund (cayman) Management L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Oncology Impact Fund (cayman) Management L.p. has not made any transactions after 2021-09-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Oncology Impact Fund (cayman) Management L.p.
Oncology Impact Fund (cayman) Management L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Oncology Impact Fund (cayman) Management L.p. owns 10 companies in total, including Oncorus Inc (ONCR) , ITeos Therapeutics Inc (ITOS) , and TCR2 Therapeutics Inc (TCRR) among others .
Insider Ownership Summary of Oncology Impact Fund (cayman) Management L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ONCR | Oncorus Inc | 2020-10-06 | 10 percent owner |
| ITOS | ITeos Therapeutics Inc | 2020-07-23 | other: X* |
| TCRR | TCR2 Therapeutics Inc | 2019-02-19 | 10 percent owner |
 | | 2021-05-27 | 10 percent owner |
| | 2017-11-02 | 10 percent owner |
| | 2017-03-25 | 10 percent owner |
| | 2017-10-27 | 10 percent owner |
| | 2017-03-25 | 10 percent owner |
| | 2021-04-29 | 10 percent owner |
| | 2021-09-16 | 10 percent owner |
Oncology Impact Fund (cayman) Management L.p. Latest Holdings Summary
Oncology Impact Fund (cayman) Management L.p. currently owns a total of 4 stocks. Among these stocks, Oncology Impact Fund (cayman) Management L.p. owns 7,648,268 shares of Cullinan Therapeutics Inc (CGEM) as of September 16, 2021, with a value of $123 Million and a weighting of 77.93%. Oncology Impact Fund (cayman) Management L.p. owns 1,278,514 shares of Harpoon Therapeutics Inc (HARP) as of May 27, 2021, with a value of $29 Million and a weighting of 18.71%. Oncology Impact Fund (cayman) Management L.p. also owns 3,370,982 shares of TCR2 Therapeutics Inc (TCRR) as of February 19, 2019, with a value of $5 Million and a weighting of 3.17%. The other 1 stocks Oncorus Inc (ONCR) have a combined weighting of 0.19% among all his current holdings.
Latest Holdings of Oncology Impact Fund (cayman) Management L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| CGEM | Cullinan Therapeutics Inc | 2021-09-16 | 7,648,268 | 16.02 | 122,525,253 |
| HARP | Harpoon Therapeutics Inc | 2021-05-27 | 1,278,514 | 23.01 | 29,418,607 |
| TCRR | TCR2 Therapeutics Inc | 2019-02-19 | 3,370,982 | 1.48 | 4,989,053 |
| ONCR | Oncorus Inc | 2020-10-06 | 2,377,025 | 0.13 | 299,505 |
Holding Weightings of Oncology Impact Fund (cayman) Management L.p.
Oncology Impact Fund (cayman) Management L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Oncology Impact Fund (cayman) Management L.p. has made a total of 9 transactions in Cullinan Therapeutics Inc (CGEM) over the past 5 years, including 1 buys and 8 sells. The most-recent trade in Cullinan Therapeutics Inc is the sale of 3,124 shares on September 16, 2021, which brought Oncology Impact Fund (cayman) Management L.p. around $90,783.
According to the SEC Form 4 filings, Oncology Impact Fund (cayman) Management L.p. has made a total of 11 transactions in Harpoon Therapeutics Inc (HARP) over the past 5 years, including 0 buys and 11 sells. The most-recent trade in Harpoon Therapeutics Inc is the sale of 1,716 shares on May 27, 2021, which brought Oncology Impact Fund (cayman) Management L.p. around $346,955.
According to the SEC Form 4 filings, Oncology Impact Fund (cayman) Management L.p. has made a total of 0 transactions in TCR2 Therapeutics Inc (TCRR) over the past 5 years. The most-recent trade in TCR2 Therapeutics Inc is the acquisition of 666,667 shares on February 19, 2019, which cost Oncology Impact Fund (cayman) Management L.p. around $10 Million.
More details on Oncology Impact Fund (cayman) Management L.p.'s insider transactions can be found in the Insider Trading History of Oncology Impact Fund (cayman) Management L.p. table.Insider Trading History of Oncology Impact Fund (cayman) Management L.p.
- 1
Oncology Impact Fund (cayman) Management L.p. Trading Performance
GuruFocus tracks the stock performance after each of Oncology Impact Fund (cayman) Management L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Oncology Impact Fund (cayman) Management L.p. is 22.45%. GuruFocus also compares Oncology Impact Fund (cayman) Management L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Oncology Impact Fund (cayman) Management L.p. within 3 months outperforms 1 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Oncology Impact Fund (cayman) Management L.p.'s insider trading performs compared to the benchmark.
Performance of Oncology Impact Fund (cayman) Management L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 18.56 | | | | | |
| Relative Return to S&P 500(%) | 15.68 | | | | | |
Oncology Impact Fund (cayman) Management L.p. Ownership Network
Ownership Network List of Oncology Impact Fund (cayman) Management L.p.
Ownership Network Relation of Oncology Impact Fund (cayman) Management L.p.
Oncology Impact Fund (cayman) Management L.p. Owned Company Details
What does Oncorus Inc do?
Who are the key executives at Oncorus Inc?
Oncology Impact Fund (cayman) Management L.p. is the 10 percent owner of Oncorus Inc. Other key executives at Oncorus Inc include Interim CEO Brian J. Shea , Interim CFO Alexander Nolte , and director & 10 percent owner & other: *Possible Member of 10% Group James E Flynn .
Oncorus Inc (ONCR) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Oncorus Inc (ONCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Oncorus Inc (ONCR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Oncorus Inc (ONCR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Oncorus Inc Insider Transactions
Oncology Impact Fund (cayman) Management L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Oncology Impact Fund (cayman) Management L.p.. You might contact Oncology Impact Fund (cayman) Management L.p. via mailing address: 450 Kendall Street, Cambridge Ma 02142.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
